表紙
市場調查報告書

焦點市場分析:末梢性T細胞淋巴瘤 (PTCL)

Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

出版商 Datamonitor Healthcare 商品編碼 633156
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
焦點市場分析:末梢性T細胞淋巴瘤 (PTCL) Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)
出版日期: 2019年12月23日內容資訊: 英文 50 Pages
簡介

全球末梢性T細胞淋巴瘤 (PTCL)的發病量預測將從2017年的19,950件,增加到2026年23,880件。大多數病例是男性,並且60歲以上的患者比例很高。迄今為止,市場上有大量治療劑,同時臨床試驗化正在加強,一些有潛力的藥物已進入II期。美國市場控制著臨床試驗,在英國和日本則活絡地進行著臨床試驗。

本報告提供全球末梢性T細胞淋巴瘤 (PTCL)的治療藥的市場調查,彙整與疾病的背景·概要,罹患數的十年預測,已上市藥物核准趨勢,主要的開發平台概要,主要的資本交易趨勢 (授權合約,資產收購等),主要藥物的銷售額預測,專利趨勢,臨床試驗狀況等資料。

概要

主要的要點

疾病的背景

  • PTCL的亞型

治療方法

流行病學

已上市藥物

開發平台藥物

近來的主要市場活動和分析師的見解

今後主要的活動

成功的可能性

授權合約·資產收購交易

母專利

商機

臨床實驗環境

  • 臨床試驗贊助者一覽:各狀況
  • 臨床試驗贊助者一覽:各期

參考文獻

  • 處方資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0184074

This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were approximately 19,950 incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and forecasts that number to increase to 23,880 incident cases by 2026. It is estimated that the majority of diagnosed cases were in males in 2017. The incidence of PTCL is highest among older individuals aged 60+ years. The approved drugs in the PTCL space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.

The majority of industry-sponsored drugs in active clinical development for PTCL are in Phase II. Therapies in development for PTCL focus on a wide variety of targets. These therapies are administered via the oral and intravenous routes.

High-impact upcoming events for drugs in the PTCL space comprise topline Phase II trial results for Zinapar and IPH4102, Phase II updated trial results for CS1001, and an expected supplemental CHMP opinion for Adcetris.

The overall likelihood of approval of a Phase I hematologic asset is 9.9%, and the average probability a drug advances from Phase III is 59.4%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been 15 licensing and asset acquisition deals involving PTCL drugs during 2014-19. The $327.5m license and supply agreement signed in 2019 between Rigel Pharmaceuticals and Grifols, to commercialize fostamatinib disodium hexahydrate in all potential indications, was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for PTCL have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.

The US has a substantial lead in the number of PTCL clinical trials globally. The UK and France lead the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the PTCL space is dominated by completed trials. Bristol-Myers Squibb has the highest number of completed clinical trials for PTCL, with nine trials.

Bristol-Myers Squibb leads industry sponsors with the highest overall number of clinical trials for PTCL, followed by Spectrum Pharmaceuticals.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • PTCL subtypes

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Copiktra for PTCL (July 25, 2019)
  • Sintilimab for PTCL (May 15, 2019)
  • Copiktra for PTCL (March 6, 2019)
  • Multiple Drugs for PTCL (January 17, 2019)
  • Copiktra for PTCL (December 3, 2018)
  • Tipifarnib (Oncology) for PTCL (December 2, 2018)
  • Campath for PTCL (November 20, 2018)
  • Adcetris for PTCL (October 1, 2018)
  • Cerdulatinib for PTCL (June 4, 2018)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Ono Licenses Rafael's Novel Chemo-Sensitizing Agent For Asia

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of PTCL, 2017-26
  • Figure 2: Incident cases of PTCL, by age, 2017
  • Figure 3: Overview of pipeline drugs for PTCL in the US
  • Figure 4: Pipeline drugs for PTCL, by company
  • Figure 5: Pipeline drugs for PTCL, by drug type
  • Figure 6: Pipeline drugs for PTCL, by classification
  • Figure 7: Sintilimab for PTCL (May 15, 2019): Phase II - ORIENT-4
  • Figure 8: Copiktra for PTCL (December 3, 2018): Phase I - w/Romidepsin or Bortezomib (TCLs) (MSKCC)
  • Figure 9: Tipifarnib (Oncology) for PTCL (December 2, 2018): Phase II - 002
  • Figure 10: Adcetris for PTCL (October 1, 2018): Phase III - ECHELON-2
  • Figure 11: Cerdulatinib for PTCL (June 4, 2018): Phase I/IIa - Two Part Dose Escalation
  • Figure 12: Key upcoming events in PTCL
  • Figure 13: Probability of success in the PTCL pipeline
  • Figure 14: Licensing and asset acquisition deals in PTCL, 2014-19
  • Figure 15: Parent patents in PTCL
  • Figure 16: Clinical trials in PTCL
  • Figure 17: Top 10 drugs for clinical trials in PTCL
  • Figure 18: Top 10 companies for clinical trials in PTCL
  • Figure 19: Trial locations in PTCL
  • Figure 20: PTCL trials status
  • Figure 21: PTCL trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of PTCL, 2017-26
  • Table 2: Incident cases of PTCL, by gender, 2017
  • Table 3: Marketed drugs for PTCL
  • Table 4: Pipeline drugs for PTCL in the US
  • Table 5: Copiktra for PTCL (July 25, 2019)
  • Table 6: Sintilimab for PTCL (May 15, 2019)
  • Table 7: Copiktra for PTCL (March 6, 2019)
  • Table 8: Multiple Drugs for PTCL (January 17, 2019)
  • Table 9: Copiktra for PTCL (December 3, 2018)
  • Table 10: Tipifarnib (Oncology) for PTCL (December 2, 2018)
  • Table 11: Campath for PTCL (November 20, 2018)
  • Table 12: Adcetris for PTCL (October 1, 2018)
  • Table 13: Cerdulatinib for PTCL (June 4, 2018)
  • Table 14: Historical global sales, by drug ($m), 2014-18
  • Table 15: Forecasted global sales, by drug ($m), 2019-23
Back to Top